Patent ID: 7579316

Claim:
A method of treating an immune reaction to an immunogenic therapeutic protein selected from the group consisting of a 30kDa TNF inhibitor, a 40kDa TNF inhibitor, and a peptide-Fc fusion molecule which binds to nerve growth factor, comprising administering a therapeutically effective amount of CTLA-4 comprising a polypeptide, selected from the group consisting of (a) SEQ ID NO: 1, (b) extracellular domain of CTLA-4, (c) residues 1-124 of SEQ ID NO:1, and (d) a variant of any of the CTLA-4 peptides (a)-(c) having a substitution of a different amino acid for Ser 25 , Ala 29 , Thr 30 , Leu 104 and/or Gly 105 relative to SEQ ID NO:1, to a subject before, during, and/or after administration of the immunogenic therapeutic protein, wherein administration of CTLA-4 decreases the incidence or intensity of an immune reaction caused by the immunogenic therapeutic protein in the subject.